Literature DB >> 31740202

Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity.

Shinichiro Fuse1, Kensuke Suzuki2, Takahiro Kuchimaru3, Tetsuya Kadonosono3, Hiroki Ueda2, Shinichi Sato1, Shinae Kizaka-Kondoh3, Hiroyuki Nakamura4.   

Abstract

HIF-1 is regarded as a promising target for the drugs used in cancer chemotherapy, and creating readily accessible templates for the development of synthetic drug candidates that could inhibit HIF-1 transcriptional activity is an important pursuit. In this study, indeno[2,1-c]pyrazolones were designed as readily available synthetic inhibitors of HIF-1 transcriptional activity. Nine compounds were synthesized in 4-5 steps from commercially available starting materials. In evaluations of the ability to inhibit the hypoxia-induced transcriptional activity of HIF-1, compound 3c showed a higher level compared with that of known inhibitor, YC-1. The compound 3c suppressed HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer chemotherapy; Fused-ring; Hypoxia-inducible factor-1; Indenopyrazolone; Pyrazole

Mesh:

Substances:

Year:  2019        PMID: 31740202     DOI: 10.1016/j.bmc.2019.115207

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Comprehensive exploration of chemical space using trisubstituted carboranes.

Authors:  Yasunobu Asawa; Saki Hatsuzawa; Atsushi Yoshimori; Kentaro Yamada; Akira Katoh; Hiroyuki Kouji; Hiroyuki Nakamura
Journal:  Sci Rep       Date:  2021-12-16       Impact factor: 4.379

Review 2.  Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review.

Authors:  Ko-Hua Yu; Hsin-Yi Hung
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.